Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666934 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL855230 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL1425995 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL29559941 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL1507770 | 0.81 | — | — | |
| SCHEMBL30384989 | 0.79 | NOTUM (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL17711300 | 0.79 | NOTUM (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL31045668 | 0.77 | CHEK1 (0.32) | — | |
| SCHEMBL13429845 | 0.77 | KDM1A (0.31) | KDM1AKCNH2KDM1B | |
| SCHEMBL32673581 | 0.77 | KDM1A (0.35) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12521368-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20180002349-A1 | New Azabenzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GBMH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-20180002349-A1 | New Azabenzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GBMH (DE) | 2018-01-04 | — | — | US | disclosed |
| EP-3245212-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170309825-A1 | NOVEL WEAK DONOR-ACCEPTOR CONJUGATED COPOLYMERS FOR FIELD- EFFECT TRANSISTOR APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170309825-A1 | NOVEL WEAK DONOR-ACCEPTOR CONJUGATED COPOLYMERS FOR FIELD- EFFECT TRANSISTOR APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170309825-A1 | NOVEL WEAK DONOR-ACCEPTOR CONJUGATED COPOLYMERS FOR FIELD- EFFECT TRANSISTOR APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016113299-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113299-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| EP-2367786-A1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010058020-A1 | NOVEL 1 -ALKYL- 3 -HYDROXY- 3 -PHENYLAZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | KDM1A 607/4885KCNH2 2205/4885KDM1B 924/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | KDM1A 2177/4885KCNH2 774/4885KDM1B 3166/4885 |
| US-20180002349-A1 | New Azabenzimidazole Derivatives | PRKAB2, PRKAB1, PRKAR2B | KDM1A 1397/4885KCNH2 2500/4885KDM1B 1386/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | KDM1A 3878/4885KCNH2 4764/4885KDM1B 4493/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | KDM1A 4193/4885KCNH2 4777/4885KDM1B 4613/4885 |
| US-20260048035-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, CD40 | KDM1A 3144/4885KCNH2 2969/4885KDM1B 3607/4885 |
| US-20250345310-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | KDM1A 4378/4885KCNH2 4767/4885KDM1B 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.